suggests that Fgr interacts with arrestin-3 at multiple sites and is consistent with the locations of disease-associated

However, an imbalance in the chemokine system can also contribute to various diseases, such as inflammatory

free fatty acid receptors (FFARs), now regarded as targets for therapeutic intervention for metabolic diseases such as liver disease, obesity and diabetes (Wold and Zhou 2018).

While these small protein GPCRs are valuable drug targets linked to serious diseases, many remain undrugged antagonist analogs have demonstrated powerful efficacies across a range of animal models spanning different disease Since many inflammatory diseases are driven by inappropriate recruitment of monocytes into tissues, CCR2 diversified portfolio of GPCR-targeted drug candidates for the treatment of cancer and other serious diseases Journal of Infectious Diseases, 199, 1525-1527. https://doi.org/10.1086/598685 · Demonstration

G protein-coupled receptors (GPCRs) have been shown to play integral roles in Alzheimer's disease pathogenesis

First complete genome sequence of lumpy skin disease virus directly from a clinical sample in South India Therapeutics Enters into Collaboration Agreement with Daiichi Sankyo to Discover Novel Medicines for CNS Diseases

GPCR Activation and Signaling Targeting GRK2 and GRK5 for treating chronic degenerative diseases: Advances

distinct from odor perception, and may contribute to the pathogenesis of disorders including brain diseases

Mutations in G protein-coupled receptors (GPCRs) underlie numerous diseases.

In the present study, we found that GB83, initially identified as a PAR2 antagonist, is a bona fide agonist Our results revealed that GB83 is a bona fide agonist of PAR2 that uniquely modulates PAR2-mediated cellular

With this high-resolution, dynamic view of GPCR activation, scientists can better tackle diseases by

Schizophrenia Sphingosine 1-phosphate receptor subtype 1 (S1P1) activity in the course of Alzheimer's disease

whether these CB1 receptors contribute to pathways underlying skeletal muscle biological function and disease

Nordisk stops Ozempic kidney trial after early signs of success Sosei and PharmEnable extend neurological disease

Immunology CCR6 as a Potential Target for Therapeutic Antibodies for the Treatment of Inflammatory Diseases

participates in inflammatory and immune responses that have been found to mediate apoptosis in autoimmune disease

studies revealed that NF-α1/CPE interacts with 5-HTR1E via 3 salt bridges, stabilized by several hydrogen bonds (ICL3) of NF-α1/CPE-5-HTR1E, it recruited β-arrestin1 by forming numerous salt bridges and hydrogen bonds

unveil new dimensions of GPCR functionality and offer innovative approaches to treating a wide range of diseases

extracellular ATP/adenosine dynamics in zebrafish models of alcoholic and metabolic steatotic liver disease

Specialized Pro-resolving Lipid Mediators and Resolution of Viral Diseases.

wakefulness LPA3 agonist-producing Bacillus velezensis ADS024 is efficacious in multiple neuroinflammatory disease

tyrosine kinase IGF1R and its associated GPCRs are co-regulated by the noncoding RNA NEAT1 in Alzheimer's disease

G protein-coupled receptors in neurodegenerative diseases and psychiatric disorders.

neuroscience drugmaker Cerevel Therapeutics for $8.7 billion FDA approves two gene therapies for sickle cell disease

Adhesion GPCRs Adhesion G Protein-Coupled Receptor Gpr126 (Adgrg6) Expression Profiling in Diseased Mouse

Neuroimmune interplay during type 2 inflammation: symptoms, mechanisms and therapeutic targets in atopic diseases

Classified GPCR News from August 14 to 20, 2023 Adhesion GPCRs Amelioration of non-alcoholic fatty liver disease

next-generation sequencing, have enabled the uncovering of associations between GPCR genetic variants and diseases